Systemic Review: Ventilator-Associated Pneumonia

Ventilator-associated pneumonia (VAP) is difficult to diagnose, and the precise role of invasive testing is controversial. Confronted with a changing clinical or radiographic setting demanding specific therapy, clinicians increasingly use invasive testing to supplement their clinical judgment. Invasive techniques include the protected-specimen brush (PSB) technique and BAL.

The PSB technique was developed in 1987 by Wimberly et al1 and has since been improved. Because it was found that samples may become contaminated by organisms of the upper airway, methods have been advanced to protect the sampling fluid. In addition, quantitative culture methods have been developed to permit distinguishing infection from colonization. However, because of concerns about diagnostic accuracy, reproducibility of results, diagnostic thresholds, nonstandardized methodology, and lack of data on clinical outcome, few definitive recommendations have been reached.2,3

The Health and Science Policy Committee of the American College of Chest Physicians assembled a panel of scientific experts to develop diagnostic recommendations based on a rigorous review of the literature. The panel included experienced methodologists to ensure that the review process was justifiable and unbiased. Recommendations were developed through group discussion and were based on direct evidence, when it was available, and expert consensus opinion, when direct evidence was not available.

To implement the evidence-based assessment, the panel adopted the following grading system for most recommendations:

Grade A: Recommendation based on direct scientific evidence;
Grade B: Recommendation based on scientific evidence, supplemented by expert opinion;
Grade C: Recommendation based on expert opinion alone; and
Grade D: There is no definitive evidence or consensus opinion.

This manuscript covers the following topic areas:

Panel methodology;
Epidemiology of VAP;
Radiologic diagnosis of VAP;
Clinical criteria in the diagnosis of VAP;
Endotracheal aspiration sampling;
BAL sampling;
The PSB technique;
Blinded, invasive diagnostic procedures; and
Invasive procedures in nonresolving pneumonia.

This executive summary reports the panelists’ major conclusions and final recommendations. The reader may assess the thoroughness of the evaluation process and the validity of the conclusions by reviewing each section.

Download Guidelines

Guideline Ranking & Disclaimer

Rank
Definition
1 This guideline is new and represents the best available evidence at this time. It will be reviewed on an annual basis to determine if it remains current.
2 This guideline is reviewed on an annual basis and there have been new studies published since the guideline was developed. However, the Health and Science Policy (HSP) Committee determined that these studies are not sufficient to warrant changing the guideline at this time. The information contained in this guideline provides the user with the best evidence available at the time the guideline was published. Readers are encouraged to search the current literature as a supplement to using this guideline.
3 This guideline is reviewed on an annual basis. The HSP Committee determined that new studies have been published that warrant an update of the (fill in) chapter/section of this practice guideline. The HSP Committee also determined that the remainder of the chapters/sections does not require updating and these recommendations remain current.
4 This guideline is reviewed on an annual basis. The HSP Committee determined that new data are available that are sufficient to potentially change guideline recommendations and a full revision is warranted.
5 This guideline has been reviewed on an annual basis. The HSP Committee has decided it is outdated; however, it has been retained for historical and/or educational purposes. These guidelines should be used with caution for clinical decision-making purposes.

The evidence-based practice guidelines published by The American College of Chest Physicians (“ACCP”) incorporate data obtained from a comprehensive literature review of the most recent studies available at the time of publication. Guidelines are intended for general information only, are not medical advice, and do not replace professional medical care and physician advice, which always should be sought for any specific condition. Furthermore, guidelines may not be complete or accurate because new studies that may have become available late in the process of guideline development may not be incorporated into any particular guideline before it is disseminated. ACCP and its officers, regents, governors, executive committee, members and employees (the “ACCP Parties”) disclaim all liability for the accuracy or completeness of a guideline, and disclaim all warranties, express or implied. Guideline users always are urged to seek out newer information that might impact the diagnostic and treatment recommendations contained within a guideline. The ACCP Parties further disclaim all liability for any damages whatsoever (including, without limitation, direct, indirect, incidental, punitive, or consequential damages) arising out of the use, inability to use, or the results of use of a guideline, any references used in a guideline, or the materials, information, or procedures contained in a guideline, based on any legal theory whatsoever and whether or not there was advice of the possibility of such damages.